Nipro (TSE:8086) Stock P/E Faces Scrutiny After One Off Gain

Nipro stock has quietly climbed about 5% over the past week and 8% over the past month, so investors came into this earnings print with expectations already running ahead of the broader medical equipment sector. The headline this quarter is not the top line. It is the profit picture, where trailing earnings have increased over the last year and pushed the P/E to 20.3x.

For you as a shareholder, the key question now is how much of that profit strength is repeatable, given the large ¥9.8b one off gain that sits inside those trailing numbers.

Is Nipro’s 20.3x P/E simply reflecting that ¥9.8b one off gain, or is the stock priced for a much more durable profit story? See how the current valuation stacks up in our valuation analysis for Nipro

Q1 2027 Earnings Summary

• Revenue (Q4 2026 vs. Q4 2025): ¥173,233m vs. ¥165,304m (higher period on period)
• Net Income, excl. extra items (Q4 2026 vs. Q4 2025): loss of ¥3,180m vs. loss of ¥1,481m (larger loss period on period)
• Basic EPS (Q4 2026 vs. Q4 2025): loss of ¥19.50 per share vs. loss of ¥9.08 per share (larger loss per share period on period)
• Trailing 12 month Revenue (FY 2026 vs. FY 2025): ¥660,538m vs. ¥644,586m (modest increase over the year)

Prefer clear visuals instead of another wall of earnings tables and footnotes? See Nipro’s full financial picture, including a concise valuation snapshot, in our company report for Nipro.

Nipro’s defensive story meets mixed profit signals

Nipro’s “defensive healthcare backbone” story finds some support in the revenue line. Revenue for Q4 2026 was ¥173,233m compared with ¥165,304m a year earlier, and trailing 12 month revenue was ¥660,538m versus ¥644,586m in FY 2025. That points to a business that is still moving product across devices, drugs, and packaging. Recent partnerships in infusion safety valves and a biosimilar launch in Japan also fit the everyday healthcare supplier idea that many investors associate with a defensive profile.

Profit drag keeps the Nipro risk debate alive

For a defensive healthcare stock, Nipro’s losses are hard to ignore. The loss, excluding extra items, widened from ¥1,481m to ¥3,180m year on year in Q4, and basic EPS loss nearly doubled over the same period. That sits awkwardly beside a narrative of steady, reliable cash generation. The recent ¥9.8b one off gain and widening quarterly loss mean profit quality is a key watchpoint for anyone focused on margin pressure in devices, generics, or contract work.

Compare Nipro’s steady revenue line and defensive healthcare profile with the widening losses and one off gains that are now embedded in trailing earnings, then ask whether the recent ¥1,671 share price already reflects everything the company has delivered. See the consensus price target analysis for Nipro

Stay Ahead With Simply Wall St

If Nipro’s mix of steady revenue and mixed profits has your attention, register for free with Simply Wall St and add it to a Watchlist to track share price against fair value and spot a potential entry that fits your plan. When you decide to take or adjust a position, use the Portfolio Command Center to cut through noise and focus only on the updates that matter to your holdings. For a longer term view, tap into crowd wisdom through the Community and see how other investors are thinking about Nipro and similar stocks. This combination can help you surface hidden catalysts and risks early and stay a step ahead of the market.

Seeking Alternatives Beyond Nipro Today

Fresh stock ideas can move from quiet to breakout quickly. Use these curated lists before momentum is fully caught, while it matters and still flies under the radar for now, and consider acting early.

• Spot companies with resilient cash flows and low debt pressure using the carefully filtered list of solid balance sheet and fundamentals stocks (40 results). Get a shortlist before there is broader interest.
• Explore potential momentum in businesses already producing real earnings through the curated set of 71 profitable AI stocks that aren't just burning cash. This can help you avoid chasing AI stories that are still burning cash.
• Zero in on companies whose balance sheets and returns skew toward stability using the focused group of 54 resilient stocks with low risk scores. Review these opportunities before valuations fully reflect their characteristics.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com